Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03128996
Recruitment Status : Recruiting
First Posted : April 26, 2017
Last Update Posted : October 2, 2019
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

Condition or disease Intervention/treatment Phase
Severe Sickle Cell Disease Bone Marrow Failure Syndromes Metabolic Disorders Immunologic Disorders Hemoglobinopathies Non-malignant Disorders Drug: RIC regimen Drug: GVHD prophylaxis regimen Phase 1 Phase 2

Detailed Description:

Patients < 21 years of age with a non-malignant disorder benefited by hematopoietic stem cell transplant will receive a reduced intensity conditioning regimen consisting of hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan.

This will be followed by a familial HLA-mismatched bone marrow transplant. The primary objective is to establish safety and donor cell engraftment at 100 days and 1 year post-transplant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
Actual Study Start Date : March 20, 2017
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RIC Prep Regimen & GVHD Prophylaxis
Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
Drug: RIC regimen
Days -60 to -21: hydroxyurea (30mg/kg/day po) >6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if < 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if < 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
Other Names:
  • Transplant Preparative Regimen
  • Transplant Conditioning Regimen

Drug: GVHD prophylaxis regimen
Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus & Start of mycophenolate mofetil (MMF) Days +30, +60, and +90: abatacept (IND) (10mg/kg/day IV)
Other Name: Graft versus Host Disease prophylaxis regimen




Primary Outcome Measures :
  1. Donor engraftment [ Time Frame: 100 days and 1 year post-transplant ]
    as measured by chimerism


Secondary Outcome Measures :
  1. Time to neutrophil engraftment [ Time Frame: 100 days post-transplant ]
    as measured by complete blood counts

  2. Time to platelet engraftment [ Time Frame: 100 days post-transplant ]
    as measured by complete blood counts

  3. Effect of BMT on pulmonary function [ Time Frame: 90 days, 1 year, and 2 years post-transplant ]
    as measured by pulmonary function tests

  4. Effect of BMT on hepatic function [ Time Frame: 90 days, 180 days, 1 year, and 2 years post-transplant ]
    as measured by laboratory evaluations

  5. Effect of BMT on neurologic function [ Time Frame: 90 days, 1 year, and 2 years post-transplant ]
    as measured by cognitive testing and quality of life surveys

  6. Effect of BMT on cardiac function [ Time Frame: 90 days, 1 year, and 2 years post-transplant ]
    as measured by echocardiograms

  7. Effect of BMT on renal function [ Time Frame: 90 days, 180 days, 1 year, and 2 years post-transplant ]
    as measured by laboratory evaluations

  8. Pharmacokinetics of alemtuzumab [ Time Frame: days -19, day 0, day +15, and day +30 ]
    as measured by maximum plasma concentration of alemtuzumab

  9. Pharmacokinetics of abatacept [ Time Frame: days +30, +60, +90, 1 year, 1.5 years, and 2 years post-transplant ]
    as measured by maximum plasma concentration of abatacept

  10. Incidence of acute graft-versus-host disease (GVHD) [ Time Frame: 1 year post-transplant ]
    as measured by protocol grading scale

  11. Incidence of chronic graft-versus-host disease (GVHD) [ Time Frame: 2 years post-transplant ]
    as measured by protocol grading scale

  12. Immune reconstitution [ Time Frame: days +30, +60, +90, 1 year, 1.5 years, and 2 years post-transplant ]
    as measured by research laboratory evaluations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Nonmalignant disorder requiring bone marrow transplant including bone marrow failure syndromes, metabolic disorders, immunologic disorders, or hemoglobinopathy
  • For patients with sickle cell disease, must have one of the following severe manifestations:

    1. Overt or silent stroke or persistently elevated transcranial doppler velocities despite transfusion therapy
    2. Recurrent acute chest syndrome with significant respiratory compromise each time
    3. Sickle nephropathy
    4. Recurrent admissions for vaso-occlusive episodes resulting in prolonged opioid use and poor quality of life with interrupted school attendance activity
    5. Red cell alloimmunization with the need for chronic transfusions
    6. Recurrent osteonecrosis or multiple joint involvement from avascular necrosis
  • Patients with sickle cell disease must have hemoglobin S < 30% within 30 days prior to beginning alemtuzumab
  • Age </= 20.99 years at the time of enrollment
  • Performance score > 50
  • Left ventricular ejection fraction > 40% or left ventricular shortening fraction > 26% by echocardiogram
  • DLCO > 40% (corrected for hemoglobin) or pulse oximetry with a baseline O2 saturation of >/= 90% on room air if too young to perform PFTs
  • Serum creatinine < 1.5x upper limit of normal for age and/or GFR > 70 mL/min/1.73m2
  • Direct bilirubin < 2x upper limit of normal for age
  • ALT and AST < 5x upper limit of normal for age
  • Participants who have or are receiving >/= 8 packed red blood cell transfusions for >/= 1 year or >/= 20 packed red blood cell transfusions (lifetime cumulative) will undergo liver MRI for estimation of hepatic iron content.

    1. Liver biopsy is indicated for hepatic iron content >/= 7mg Fe/mg liver dry weight by liver MRI.

Histologic examination of the liver must document for the absence of cirrhosis, bridging fibrosis, and active hepatitis

Exclusion Criteria:

  • Patients who have an HLA-identical sibling who is able and willing to donate bone marrow
  • Patients with cirrhosis or established bridging fibrosis of the liver or active hepatitis
  • Uncontrolled bacterial, viral, or fungal infection within 6 weeks prior to enrollment
  • Evidence of HIV infection or known HIV positive serology
  • Patients who have received a previous stem cell transplant
  • Patients who have received an investigational drug or device or off-label use of a drug or device within 3 months of enrollment
  • Females who are pregnant or breast feeding
  • Patients with active autoimmune disease (e.g. sarcoidosis, lupus, scleroderma)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03128996


Contacts
Layout table for location contacts
Contact: Shalini Shenoy, MD 314-454-6018 shalinishenoy@wustl.edu
Contact: Lisa Murray, MA, CCRP 314-454-4240 murraylm@wustl.edu

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Shalini Shenoy, MD    314-454-6018    shalinishenoy@wustl.edu   
Contact: Lisa Murray, MA, CCRP    314-454-4240    murraylm@wustl.edu   
Principal Investigator: Shalini Shenoy, MD         
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Shalini Shenoy, MD Washington University School of Medicine

Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT03128996    
Other Study ID Numbers: 201611172
First Posted: April 26, 2017    Key Record Dates
Last Update Posted: October 2, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Washington University School of Medicine:
Bone marrow transplant
Transplant
Transplantation
Reduced Intensity
Familial HLA mismatched
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Hemoglobinopathies
Pancytopenia
Metabolic Diseases
Disease
Immune System Diseases
Pathologic Processes
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn